Update on Helicobacter pylori treatment
- PMID: 17304866
Update on Helicobacter pylori treatment
Abstract
One half of the world's population has Helicobacter pylori infection, with an estimated prevalence of 30 percent in North America. Although it is unclear whether eradication of H. pylori improves symptoms in patients with nonulcer dyspepsia, there is strong evidence that eradication of this bacteria improves healing and reduces the risk of recurrence or rebleeding in patients with duodenal or gastric ulcer. A "test-and-treat" strategy is recommended for most patients with undifferentiated dyspepsia. With this approach, patients undergo a noninvasive test for H. pylori infection and, if positive, are treated with eradication therapy. This strategy reduces the need for antisecretory medications as well as the number of endoscopies. The urea breath test or stool antigen test is recommended. Until recently, the recommended duration of therapy for H. pylori eradication was 10 to 14 days. Shorter courses of treatment (i.e., one to five days) have demonstrated eradication rates of 89 to 95 percent with the potential for greater patient compliance. A one-day treatment course consists of bismuth subsalicylate, amoxicillin, and metronidazole, all given four times with a one-time dose of lansoprazole. In children with documented H. pylori infection, however, all regimens should continue to be prescribed for seven to 14 days until short-course treatment is studied and its effectiveness has been established in this population.
Comment in
-
Update on the treatment of patients with Helicobacter pylori.Am Fam Physician. 2007 Sep 1;76(5):633. Am Fam Physician. 2007. PMID: 17894129 No abstract available.
-
Risks of H. pylori "test-and-treat" strategy in dyspepsia.Am Fam Physician. 2008 Jan 15;77(2):146. Am Fam Physician. 2008. PMID: 18246884 No abstract available.
Similar articles
-
Update on the treatment of patients with Helicobacter pylori.Am Fam Physician. 2007 Sep 1;76(5):633. Am Fam Physician. 2007. PMID: 17894129 No abstract available.
-
Guidelines in the medical treatment of Helicobacter pylori infection.J Physiol Pharmacol. 2006 Sep;57 Suppl 3:143-54. J Physiol Pharmacol. 2006. PMID: 17033112
-
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.Hepatogastroenterology. 2007 Jun;54(76):1293-6. Hepatogastroenterology. 2007. PMID: 17629092
-
Helicobacter pylori and non-malignant diseases.Helicobacter. 2006 Oct;11 Suppl 1:27-31. doi: 10.1111/j.1478-405X.2006.00426.x. Helicobacter. 2006. PMID: 16925608 Review.
-
Management of Helicobacter pylori infection.Am Fam Physician. 2002 Apr 1;65(7):1327-36. Am Fam Physician. 2002. PMID: 11996414 Review.
Cited by
-
Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori.Ann Trop Med Parasitol. 2011 Apr;105(3):251-9. doi: 10.1179/136485911X12899838683485. Ann Trop Med Parasitol. 2011. PMID: 21801504 Free PMC article.
-
Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases.Front Microbiol. 2021 Aug 9;12:689958. doi: 10.3389/fmicb.2021.689958. eCollection 2021. Front Microbiol. 2021. PMID: 34434175 Free PMC article. Review.
-
Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with Helicobacter pylori: a case-control study.Hematol Transfus Cell Ther. 2018 Apr-Jun;40(2):160-165. doi: 10.1016/j.htct.2017.11.010. Epub 2018 Feb 17. Hematol Transfus Cell Ther. 2018. PMID: 30057990 Free PMC article.
-
Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia.Antimicrob Agents Chemother. 2009 Sep;53(9):4022-4. doi: 10.1128/AAC.00145-09. Epub 2009 Jun 22. Antimicrob Agents Chemother. 2009. PMID: 19546360 Free PMC article.
-
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.J Gastroenterol. 2023 Jul;58(7):633-641. doi: 10.1007/s00535-023-01991-y. Epub 2023 Apr 12. J Gastroenterol. 2023. PMID: 37042991 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical